BUREN has advised Alimera Sciences, Inc., a pharmaceutical company listed on the Nasdaq that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, on the refinancing of its existing debt with Solar Capital Ltd. Alimera Sciences Inc.
Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in Alimera’s product and development portfolio designed to treat early- and late-stage diseases.
Solar Capital Ltd. is a closed-end investment company that has elected to be treated as a business development company under the Investment Company Act of 1940. A specialty finance company with expertise in several niche markets, Solar Capital primarily invests in leveraged, U.S. middle market companies in the form of senior secured cash flow and asset-based investments. Solar Capital’s life science lending business provides financing solutions for bio-pharma, medical device, healthcare IT and healthcare services companies, both venture-backed private and public, and from pre-revenue clinical to early commercial stage.
BUREN is delighted to welcome Martijn van der Vliet and
With its strong infrastructure, ideal location between major European markets like the UK,
Lous Vervuurt, lawyer at BUREN, has written the Netherlands chapter of the Global Legal Insights - Banking Regulation 2021. The GLI – Banking Regulation 2021